期刊
VACCINES
卷 9, 期 3, 页码 -出版社
MDPI
DOI: 10.3390/vaccines9030296
关键词
COVID-19; vaccine; neutralizing antibodies; adjuvant
资金
- National Key Research and Development Plan grant [2017YFA0505901]
- Fundamental Research Funds for the Central Universities [22120200163]
- National Natural Science Foundation of China [31870972]
- Shanghai Science and Technology Commission [15002360172]
- Outstanding Clinical Discipline Project of Shanghai Pudong [PWYgy2018-10]
The study investigated the efficacy of a recombinant trimeric Spike protein as a potential COVID-19 vaccine candidate, showing it induced Spike protein-specific antibodies with high titers and neutralizing capabilities. The identified immunodominant receptor-binding domain (RBD) and linear epitopes in different regions contribute to its potential effectiveness against the virus.
The structures of immunogens that elicit the most potent neutralization antibodies to prevent COVID-19 infection are still under investigation. In this study, we tested the efficacy of a recombinant trimeric Spike protein containing polyI:C (PIKA) adjuvant in mice immunized by a 0-7-14 day schedule. The results showed that a Spike protein-specific antibody was induced at Day 21 with titer of above 50,000 on average, as measured by direct binding. The neutralizing titer was above 1000 on average, as determined by a pseudo-virus using monoclonal antibodies (40592-MM57 and 40591-MM43) with IC50 at 1 mu g/mL as standards. The protein/peptide array-identified receptor-binding domain (RBD) was considered as immunodominant. No linear epitopes were found in the RBD, although several linear epitopes were found in the C-terminal domain right after the RBD and heptad repeat regions. Our study supports the efficacy of a recombinant trimeric Spike protein vaccine candidate for COVID-19 that is safe and ready for storage and distribution in developing countries.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据